Global In Vitro Diagnostics Sector Prospects in Emerging Markets.pdf
《Global In Vitro Diagnostics Sector Prospects in Emerging Markets.pdf》由会员分享,可在线阅读,更多相关《Global In Vitro Diagnostics Sector Prospects in Emerging Markets.pdf(39页珍藏版)》请在三一文库上搜索。
1、Global In-vitro Diagnostics Sector- Prospects in Emerging Markets A the demand for IVD Immunoassays is expected to reach US$6.0 billion by 2013. Table 2.1: In-Vitro Diagnostics Demand Forecast (2003, 2008 & 2013) 2003 2008 2013F IVD Product Demand 13.17 18.00 23.3 Clinical Chemistry 5.05 6.50 8.9 Im
2、munoassays 3.18 4.30 6.0 Blood Testing 1.54 1.90 1.9 Nucleic Acid Testing 0.90 1.68 2.4 Other 2.5 3.62 4.1 Note: Figures in US$ Billions Source: A&M MindPower Solutions Home health care is expected to be the fastest growing segment from 2008 to 2013, while hospital laboratories will remain the large
3、st market. 3. IVD Market in Europe 3.1 Market Overview The total European IVD market is valued at US$14.73 billion, growth was in the range of 4.2% versus 2007 (US$14.24 billion) and the market is expected to have a slow growth, which is attributed to the increase in the adoption of new technologies
4、 in the market. There has been an increased awareness about emerging technologies, especially, in areas such as molecular testing amongst patients and laboratories. Laboratories have also become aware for the need for automation, which has fuelled the growth of this market. This opportunity has bein
5、g utilised by IVD manufacturers, who are developing innovating laboratory analysers and other automated solutions along with introducing new technologies in order to grow within the European market. There are more than 60 companies in the clinical diagnostics market including large pharmaceutical co
6、mpanies with diagnostic divisions such as Roche Diagnostics, Bayer Diagnostics and Abbott Diagnostics that have particular advantages in terms of disease management initiatives because they have stakes in both the therapeutic and diagnostic sectors of the healthcare industry. These companies are fol
7、lowed by medium firms that include diagnostic companies specifically focusing on the manufacturing, distributing and marketing of diagnostic test kits and analysers such as BioMerieux and Bio-Rad laboratories. Lastly, the market consists of biotechnology companies, which focus on the development of
8、technology for novel diagnostic methods such as Affymetrix, Digene and Gen-Probe. The distribution structure involves mainly catalogue and direct sales and the main competitive factors include product line, price, quality, service, brand recognition and product life span. Though the IVD market is re
9、aching maturity stage in Europe, the genomics revolution combined with developments in automation technology have definitely set the pace in the market. Today with well established segments in the IVD market moving towards maturity, advancements in the above two fields along with popularity for poin
10、t-of-care testing (POCT) is balancing the growth in the IVD market. Due to the growing trend of the de-centralisation of testing in Europe, suppliers have focussed on this segment which traditionally accounted for a low proportion of the total income. By 2009, however, up to 30% of all tests are lik
11、ely to have shifted towards the community care level, with home-testing becoming more popular as well. Central and eastern European regions represent potentially lucrative markets yet to be fully exploited. However, IVD suppliers looking to establish themselves in these geographies must still conten
12、d with a variety of commercialisation issues such as parallel imports, distribution channels and regulations. The expenditure on IVDs in comparison to the total healthcare expenditure was 0.8% i.e. US$33.66 per capita, by original EU 15 countries while the later joining member states had an average
13、of 1.3% of the total healthcare expenditure to IVDs i.e. US$10.73 per capita. The most IVD sales in Europe can be accounted to the ageing population in need for routine testing principally for metabolic and cardiovascular diseases and also for infections from hospitals. The deficits in the healthcar
14、e budget in most of the European markets have resulted in closure of small hospitals and laboratories, rationalisation of testing and also delay in the introduction and reimbursement of new IVD tests. Laboratory consolidation is one of the very important elements in selecting IVD suppliers, because
15、it leads to an increasing need of pre & post analytical systems & IT solutions. Big global operating laboratories are looking out for takeovers and even the French labs are looking out for opportunities to merge or invest in international laboratory chains. In Italy, there has been a reduction in th
16、e number of hospitals as well as the number of days a patient spends in the hospital. There has been an increased amount of mergers taking place in the private laboratories segment as small labs are being taken over by big laboratories or are integrated into their networks. In the recent years, Germ
17、any has been one of the most sluggish European markets, although having a considerable portion of ageing population. The consolidation phase in the laboratory market continues with private laboratories targeting hospital market by purchasing them or operating them on behalf of hospital administratio
18、n. The acquisition trend in this sector has led to creation of purchasing groups which are impacting the value market growth. In Austria, a similar trend is being followed as in the other European countries. A move towards centralisation of labs and structuring of buyer networks can be observed. The
19、se trends in context with budget constraints will have a major impact on the market growth in future. In Spain, the IVD market is witnessing growth in recent years. A similar trend of Lab centralisation continues and also materialization of specialist satellite labs. UK has been facing burden of fun
20、ding for the National Healthcare System (NHS) which means the earlier investments have been considerably reduced & cost savings programmes would be put into practice. In Netherlands, because of the changes in the mechanism of hospital financing, there is a tendency towards partnership, centralisatio
21、n and sub contracting. Labs are seeking to win over the hospital organisation and health care insurance providers by providing better patient management. In Belgium, merging of labs and formation of hospital networks have led to creation of centralised purchasing power. Table 3.1: IVD Market Statist
22、ics 2008 Population GDP IVD Market in 2008 Growth Rate 08 IVD Market est. per capita 08 Countries Thousand US$ Mill US$ Mill % US$ EU-15 Germany 82,257 3561663 3097.29 3 37.632 France 61,707 2781434 2431.38 4 39.396 UK 60,975 2594381 1059.87 11.2 17.346 Italy 58,880 2271025 2388.75 2.7 40.572 Spain
23、44,873 1559075 1525.86 7 33.957 Netherlands 16,382 833587 438.06 3.8 26.754 Greece 11,193 335318.8 338.1 0 30.135 Portugal 10,604 239784.9 358.68 -1.2 33.81 Belgium 10,623 492328 463.05 5.7 43.512 Sweden 9,148 469215.2 241.08 1.6 26.313 Austria 8,315 398130.4 348.39 4.3 41.895 Denmark 5,457 332803.6
24、 179.34 5.2 32.928 Finland 5,289 264098.7 144.06 -1 27.195 Ireland 4,339 280186.4 119.07 3.8 27.489 Luxembourg 476 53328.66 EU-27 Poland 38,121 494806.4 405.72 11.4 10.584 Romania 21,565 162455.6 114.66 2.6 5.292 Czech Republic 10,323 208356.3 220.5 3.8 21.315 Hungary 10,056 149465.2 89.67 5.5 8.967
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- Global In Vitro Diagnostics Sector Prospects Emerging Markets
链接地址:https://www.31doc.com/p-3767033.html